​

Checkpoint Therapeutics (CKPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CKPT Stock Forecast

Checkpoint Therapeutics (CKPT) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $4.10, with a high of $4.10 and a low of $4.10. This represents a 1.99% increase from the last price of $4.02.

High: $4.1 Avg: $4.1 Low: $4.1 Last Closed Price: $4.02

CKPT Stock Rating

Checkpoint Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (71.43%), 2 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 2 5 Strong Sell Sell Hold Buy Strong Buy

CKPT Price Target Upside V Benchmarks

TypeNameUpside
StockCheckpoint Therapeutics1.99%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$4.10$4.10
Last Closing Price$4.02$4.02$4.02
Upside/Downside-1.99%1.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-12--3
Mar, 2512---3
Feb, 2512---3
Jan, 2513---4
Dec, 2412---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 11, 2025H.C. Wainwright$4.10$4.002.50%1.99%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 11, 2025H.C. WainwrightNeutraldowngrade
Dec 19, 2022B. Riley SecuritiesBuyBuyhold
Jun 09, 2021B. RileyBuyinitialise
Jan 22, 2021Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.11$-7.45$-7.57$-2.77$-1.42----
Avg Forecast$-3.23$-5.08$-5.69$-2.68$-0.88$-0.12$0.92$5.99$2.12
High Forecast$-1.54$-2.43$0.02$-2.43$-0.84$0.01$1.41$9.21$3.26
Low Forecast$-4.91$-7.73$-11.41$-2.92$-0.90$-0.19$-0.06$-0.38$-0.14
Surprise %27.24%46.65%33.04%3.36%61.36%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.07M$268.00K$192.00K$103.00K-----
Avg Forecast$1.11M$370.40K$123.60K$99.25K$28.25K$51.81M$185.71M$914.91M$383.70M
High Forecast$1.56M$519.19K$219.07K$132.33K$39.92K$73.22M$262.41M$1.29B$542.19M
Low Forecast$664.42K$221.61K$28.13K$66.17K$5.13K$9.40M$33.69M$165.98M$69.61M
Surprise %-3.74%-27.65%55.34%3.78%-----

Net Income Forecast

$-250M $-160M $-70M $20M $110M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.96M$-56.62M$-66.92M$-51.85M$-56.24M----
Avg Forecast$-60.44M$-95.21M$-106.69M$-51.85M$-16.31M$-1.70M$12.70M$82.67M$39.73M
High Forecast$-28.88M$-45.49M$444.90K$-45.56M$-15.68M$148.30K$26.50M$172.55M$61.07M
Low Forecast$-92.01M$-144.93M$-213.83M$-54.74M$-16.94M$-3.55M$-1.11M$-7.20M$-2.55M
Surprise %-62.01%-40.54%-37.28%-244.83%----

CKPT Forecast FAQ

Is Checkpoint Therapeutics stock a buy?

Checkpoint Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Checkpoint Therapeutics is a favorable investment for most analysts.

What is Checkpoint Therapeutics's price target?

Checkpoint Therapeutics's price target, set by 7 Wall Street analysts, averages $4.1 over the next 12 months. The price target range spans from $4.1 at the low end to $4.1 at the high end, suggesting a potential 1.99% change from the previous closing price of $4.02.

How does Checkpoint Therapeutics stock forecast compare to its benchmarks?

Checkpoint Therapeutics's stock forecast shows a 1.99% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Checkpoint Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Checkpoint Therapeutics’s EPS forecast?

Checkpoint Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.12, marking a -91.55% decrease from the reported $-1.42 in 2024. Estimates for the following years are $0.92 in 2026, $5.99 in 2027, and $2.12 in 2028.

What is Checkpoint Therapeutics’s revenue forecast?

Checkpoint Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $51.81M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $185.71M, followed by $914.91M for 2027, and $383.7M for 2028.

What is Checkpoint Therapeutics’s net income forecast?

Checkpoint Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-1.702M, representing a -96.97% decrease from the reported $-56.24M in 2024. Projections indicate $12.7M in 2026, $82.67M in 2027, and $39.73M in 2028.